EMBCHealthcare · Medical Instruments & SuppliesThe 4 Wall Street analysts covering Embecta Corp. hold a median 12-month price target of $4 — -9.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 75 of 100 as at 8 Aug 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Embecta Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Momentum (9): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own Embecta Corp. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on EMBC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits −9.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 May 2026 | B of A Securities | Maintains | Underperform | $11 → $3.00 |
| 6 May 2026 | BTIG | Downgrade | Neutral | — |
| 6 May 2026 | Mizuho | Maintains | Neutral | — |
| 13 Apr 2026 | Mizuho | Maintains | Neutral | — |
| 6 Feb 2026 | BTIG | Reiterates | Buy | — |
| 5 Sept 2025 | BTIG | Reiterates | Buy | — |
| 16 July 2025 | Mizuho | Maintains | Neutral | — |
| 23 May 2025 | Mizuho | Maintains | Neutral | — |
| 10 Apr 2025 | Mizuho | Initiates | Neutral | — |
| 27 Nov 2024 | BTIG | Upgrade | Buy | — |
| 15 July 2024 | Morgan Stanley | Maintains | Underweight | — |
| 10 May 2024 | Morgan Stanley | Maintains | Underweight | — |
| 22 Nov 2023 | Morgan Stanley | Maintains | Underweight | — |
| 18 Oct 2023 | Morgan Stanley | Maintains | Underweight | — |
| 24 Aug 2023 | Morgan Stanley | Maintains | Underweight | — |
| 18 July 2023 | Morgan Stanley | Maintains | Underweight | — |
| 15 May 2023 | Morgan Stanley | Maintains | Underweight | — |
| 6 Jan 2023 | Morgan Stanley | Downgrade | Underweight | — |
| 21 Dec 2022 | Morgan Stanley | Maintains | Equal-Weight | — |
| 11 Oct 2022 | Morgan Stanley | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 68% of US stocks
Cheaper than 91% of US stocks
Cheaper than 93% of US stocks
Cheaper than 54% of US stocks
Higher than 17% of US stocks
Higher than 9% of US stocks
Higher than 72% of US stocks
Higher than 77% of US stocks
Higher than 67% of US stocks
Higher than 34% of US stocks
Higher than 97% of US stocks
Higher than 21% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EMBC appears on the weeks it earns a place.
Embecta Corp. released the transcript of its Q3 2026 earnings call, as published by Seeking Alpha. The transcript covers management's discussion of the company's third-quarter fiscal 2026 results.
Why it matters — The earnings call transcript gives EMBC watchers a direct account of management's commentary on the company's most recent quarterly results.
Rosen Law Firm reminded Embecta Corp. investors who purchased common stock between November 25, 2025 and May 4, 2026 of the August 17, 2026 lead plaintiff deadline in a securities fraud lawsuit. Eligible purchasers may seek compensation through a contingency fee arrangement without out-of-pocket fees.
Why it matters — EMBC watchers would care because a securities fraud class action is pending against the company, with a lead plaintiff deadline approaching for affected shareholders.
Kaplan Fox & Kilsheimer LLP announced that a class action lawsuit has been filed against Embecta Corp. on behalf of investors who purchased or acquired Embecta securities between November 25, 2025 and May 4, 2026. The firm notified investors of an upcoming lead plaintiff deadline of August 17, 2026.
Why it matters — EMBC watchers would care because the class action lawsuit and the lead plaintiff deadline signal potential legal exposure and litigation risk for the company related to the specified class period.
Embecta reported fiscal third-quarter 2026 revenue of approximately $272 million, down 8.1% year-over-year on a reported basis and 8.9% on an adjusted constant-currency basis. The company noted results improved sequentially from the fiscal second quarter, with revenue rising about $50 million, GAAP operating income increasing about $14 million, and adjusted operating income increasing about $21 million.
Why it matters — A Embecta watcher would care because the sequential improvement in revenue and operating income offers a clearer picture of the company's current financial trajectory beyond the year-over-year decline.
Embecta Corp. reported its third quarter fiscal 2026 financial results on August 7, 2026, as announced via GlobeNewsWire. The company, which is advancing its insulin delivery legacy toward becoming a broad-based medical supplies company, disclosed its quarterly financial performance.
Why it matters — The quarterly financial results provide EMBC watchers with an update on the company's performance and progress in its transition toward a broad-based medical supplies business.
The 4 Wall Street analysts covering Embecta Corp. have a median 12-month price target of $4, with estimates ranging from $3 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Embecta Corp., 0 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Embecta Corp. 75 out of 100 across roughly 4,600 US stocks as at 8 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Aug 2026, Embecta Corp. ranks 75 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies -9.5% from the last close, and Ticker Nerd's factor model ranks Embecta Corp. 75 out of 100 as at 8 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Embecta Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EMBC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $5 over the next 12 months.
Embecta Corp. returned -55.6% over the 12 months to 7 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Embecta Corporation is a dynamic player in the healthcare industry, primarily focused on producing advanced medical devices. Its chief function is to innovate and manufacture devices related to diabetes care, addressing both individual and clinical needs.
The most recent item we track (Seeking Alpha, 7 Aug 2026): "Embecta Corp. (EMBC) Q3 2026 Earnings Call Transcript". Embecta Corp. released the transcript of its Q3 2026 earnings call, as published by Seeking Alpha. The transcript covers management's discussion of the company's third-quarter fiscal 2026 results.
Embecta Corporation is a dynamic player in the healthcare industry, primarily focused on producing advanced medical devices. Its chief function is to innovate and manufacture devices related to diabetes care, addressing both individual and clinical needs. The corporation plays a crucial role in providing solutions that facilitate the management of diabetes, which is a growing global health concern. Embecta's products are characterized by their reliability and ease of use, significantly impacting the quality of life for patients and assisting healthcare providers in delivering efficient diabetes management. With a strong emphasis on research and development, Embecta Corporation aims to address the ever-evolving medical necessities associated with diabetes. The company operates globally, ensuring broad access to its innovative medical solutions, thereby positioning itself as a vital contributor to the advancement of healthcare technologies and patient care. Through its continued dedication to excellence and innovation, Embecta Corporation holds significant market relevance, serving both individual customers and larger healthcare systems worldwide.
CEO Mr. Devdatt Kurdikar Ph.D. · 2,100 employees · United States · https://www.embecta.com